Paritaprevir (ABT-450) is a potent, orally active and antiviralnon-structural protein 3/4A (NS3/4A) proteaseinhibitor with EC₅₀s of 1 and 0.21 nM againstHCV1a and 1b, respectively. Paritaprevir is also aSARS-CoV3CL^proinhibitor with an IC₅₀of 1.31 μM. Paritaprevir is metabolized primarily bycytochrome P450(CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor)^[1][2][3][4].

EC₅₀: 1 nM (HCV 1a), 0.21 nM (HCV 1b)^[1]
IC₅₀: 1.31 μM (SARS-CoV 3CL^pro)^[3]

Paritaprevir hasin vitroantiviral activity against HCV GT1-4 and GT6 (EC₅₀range, 0.09 to 19 nM), with an EC₅₀of 0.09 nM against GT4a^[2].

The combination of Paritaprevir,Ritonavir,Ombitasvir(an NS5A protein inhibitor), andDasabuvir(an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections^[1][4].
The acute toxicity of Paritaprevir is considered to be low. Single oral doses of ≤600 mg/kg in rats and ≤100 mg/kg in dogs produces no mortality and were well tolerated. However, since Paritaprevir is administered without ritonavir as a PK enhancer, the exposures are low, especially in male rats (rat 600 mg/kg, males: C_max1.82 μg/mL, AUC_0-248.89 μg·h/mL; dog 100 mg/kg, mean: C_max61.3 μg/mL, AUC_0-24285 μg·h/mL).

765.88

Solid

C₄₀H₄₃N₇O₇S

1216941-48-8

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

DMSO : ≥ 125 mg/mL(163.21 mM)

H₂O : ≥ 0.1 mg/mL(0.13 mM)

*"≥" means soluble, but saturation unknown.

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: ≥ 2.08 mg/mL (2.72 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (2.72 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 2.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 2.08 mg/mL (2.72 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (2.72 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。